Published online Oct 24, 2023. doi: 10.5306/wjco.v14.i10.373
Peer-review started: July 30, 2023
First decision: August 24, 2023
Revised: September 7, 2023
Accepted: September 18, 2023
Article in press: September 18, 2023
Published online: October 24, 2023
Processing time: 85 Days and 17.5 Hours
Gastric cancer (GC) is a common malignant tumor of the digestive system. Disulfidptosis is a new programmed cell death mechanism, although its specific mechanism in GC is incompletely understood.
In this study, we used bioinformatics analysis to explore a disulfidptosis-based predictive model related to GC prognosis and to identify potential therapeutic targets and sensitive drugs for GC.
We extracted GC-related data from The Cancer Genome Atlas and Gene Expression Omnibus databases. R software (version 4.2.1) was used for correla
Through the above analysis, we found that the disulfidptosis related gene may be related to the prognosis of GC. Six genes, namely, PLS3, GRP, APOD, SGCE, COL8A1, and VAMP7, were found to constitute a predictive model for GC prognosis. APOD is a potential therapeutic target for treating GC. Bosutinib and other drugs are sensitive for the treatment of GC.
The results of this study indicate that disulfidptosis is related to the prognosis and treatment of GC, while APOD represents a potential therapeutic target for GC.
Core Tip: Gastric cancer (GC) is a common malignant tumor of the digestive system. Disulfidptosis is a new programmed cell death mechanism. The specific mechanism of disulfidptosis in GC is not fully understood. This study found that the disulfidptosis related gene may be related to the prognosis of gastric cancer. PLS3, GRP, APOD, SGCE, COL8A1, VAMP7, these six genes constitute a predictive model for gastric cancer prognosis. APOD is a potential therapeutic target. Bosutinib and other drugs are sensitive for the treatment of gastric cancer.